Cepheid and BioGX announced on Monday a collaboration to develop a monkeypox assay on the GeneXpert system. Financial and other terms of the deal were not disclosed.
The assay will be delivered as part of Cepheid’s FleXible Cartridge program for the GeneXpert, a system that has an installed base of more than 40,000 instruments in 180 countries, the firms noted in a statement.
“Our FleXible Cartridge program gives Cepheid the ability to work with external partners to develop accurate tests quickly when the need arises,” said David Persing, Cepheid’s executive VP and CSO, in a statement. Read Full Article